Forest Laboratories Announces Nesli Basgoz, M.D. Named to Board of Directors
May 18 2006 - 3:26PM
PR Newswire (US)
NEW YORK, May 18 /PRNewswire-FirstCall/ -- Forest Laboratories,
Inc. (NYSE:FRX) announced today Nesli Basgoz, M.D., has been named
to the Board of Directors. Dr. Basgoz was elected to serve
unanimously by board members at the Company's regularly scheduled
board of directors meeting held today in New York. (Logo:
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) Howard
Solomon, Chairman and CEO of Forest commented: "Dr. Basgoz is a
brilliant and dedicated physician and researcher, primarily in the
field of infectious disease. She has received significant academic
appointments early in her career at the Harvard Medical School and
Massachusetts General Hospital. "Medical science is essentially the
basis for all that we do and we expect Dr. Basgoz's insights,
experience and extraordinary intelligence to be valuable as we go
forward in developing and acquiring new product opportunities." Dr.
Basgoz is currently a Physician in Medicine at Massachusetts
General Hospital and Associate Chief for Clinical Affairs in its
Division of Infectious Disease. She is also Director, Infectious
Disease Outpatient Services and Director, HIV Clinical Services. Dr
Basgoz is also an Associate Professor of Medicine at Harvard
Medical School. Dr. Basgoz holds a M.D. from Northwestern
University in Chicago, Illinois and is Board Certified in both
Internal Medicine and a subspecialty of Infections Disease. About
Forest Laboratories Forest Laboratories (http://www.frx.com/) is a
US-based pharmaceutical company dedicated to identifying,
developing and delivering products that make a positive difference
in peoples' lives. Forest Laboratories' growing product line
includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for
adults for the initial and maintenance treatment of major
depressive disorder and for generalized anxiety disorder;
Namenda(R) (memantine HCl), an N-methyl-D- aspartate
(NMDA)-receptor antagonist indicated for the treatment of moderate
to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil),
an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan
medoxomil- hydrochlorothiazide), an angiotensin receptor blocker
and diuretic combination product, each indicated for the treatment
of hypertension; and Campral(R)* (acamprosate calcium), indicated
in combination with psychosocial support for the maintenance of
abstinence from alcohol in patients with alcohol dependence who are
abstinent at treatment initiation. *Benicar is a registered
trademark of Sankyo Pharma, Inc., and Campral is a registered
trademark of Merck Sante s.a.s., subsidiary of Merck KGaA,
Darmstadt, Germany. Except for the historical information contained
herein, this release contains "forward-looking statements" within
the meaning of the Private Securities Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in the
Forest Laboratories' SEC reports, including the Company's Annual
Report on Form 10-K for the fiscal year ended March 31, 2005, and
on form 10-Q for the periods ended June 30 ,2005, September 30,
2005 and December 31, 2005.
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGODATASOURCE:
Forest Laboratories, Inc. CONTACT: Charles E. Triano, Vice
President - Investor Relations of Forest Laboratories, Inc.,
+1-212-224-6714, Web site: http://www.frx.com/
Copyright
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Sep 2023 to Sep 2024